$NRXP

NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.

NRx Pharmaceuticals is positioned for near-term FDA approval of KETAFREE (preservative-free ketamine), addressing critical supply chain and safety issues while solving strategic FDA goals. The company has resolved the only outstanding FDA concern (luer lock vial attestation) and has significant pre-launch commercialization momentum, with share price expected to respond positively to ANDA approval and subsequent NDA filings.